Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

4(57.1%)

N/A

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07516353Not ApplicableNot Yet Recruiting

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

Role: collaborator

NCT02574728Phase 2Active Not Recruiting

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Role: collaborator

NCT05096923Recruiting

UNC Childhood, Adolescent, and Young Adult Cancer Cohort

Role: collaborator

NCT05268315Not ApplicableCompleted

A Brief Parental Intervention on Learning and Education in Childhood Cancer

Role: collaborator

NCT02457845Phase 1Completed

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

Role: collaborator

NCT02484261Phase 1Terminated

Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

Role: collaborator

NCT02264873Phase 1Completed

Phase I, Dose Escalation Study of Decitabine

Role: collaborator

NCT01670175Phase 1Completed

Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors

Role: collaborator

All 8 trials loaded